CommercialCoverageMedium impact
08.00.04b, crizanlizumab-tmca (Adakveo®)
Independence Blue Cross·Hematology, Oncology, Internal Medicine +1 more·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
IBX has updated the medical policy for crizanlizumab-tmca (Adakveo®), affecting medical necessity criteria, medical coding, and general guidelines. This policy change impacts coverage and billing requirements for this specialty medication used to prevent vaso-occlusive crises in sickle cell disease patients.
Action Required
By July 28, 2025: Billing team must review updated medical necessity criteria for crizanlizumab-tmca (Adakveo®) and update billing procedures accordingly. Providers should review new coding guidelines and documentation requirements for this medication. Contact IBX for specific policy details using the provided URL.